دورية أكاديمية
COVID 19 vaccine in patients of hypercoagulable disorders: a clinical perspective.
| العنوان: | COVID 19 vaccine in patients of hypercoagulable disorders: a clinical perspective. |
|---|---|
| المؤلفون: | John NA; Department of Physiology, All India Institute of Medical Sciences, Bibinagar, Telangana, India., John J; Department of Biochemistry, All India Institute of Medical Sciences, Nagpur, Maharashtra, India., Kamble P; Department of Physiology, All India Institute of Medical Sciences, Bibinagar, Telangana, India., Singhal A; Department of Physiology, All India Institute of Medical Sciences, Bibinagar, Telangana, India., Daulatabad V; Department of Physiology, RVM Medical College & Hospital, Siddipet, Telangana, Hyderabad, India., Vamshidhar IS; Department of Physiology, All India Institute of Medical Sciences, Bibinagar, Telangana, India. |
| المصدر: | Hormone molecular biology and clinical investigation [Horm Mol Biol Clin Investig] 2021 Nov 17; Vol. 43 (1), pp. 89-96. Date of Electronic Publication: 2021 Nov 17. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: De Gruyter Country of Publication: Germany NLM ID: 101538885 Publication Model: Electronic Cited Medium: Internet ISSN: 1868-1891 (Electronic) Linking ISSN: 18681883 NLM ISO Abbreviation: Horm Mol Biol Clin Investig Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Berlin : De Gruyter |
| مواضيع طبية MeSH: | COVID-19*/complications , COVID-19*/prevention & control , Thrombocytopenia*/complications , Thrombosis*/etiology , Thrombosis*/prevention & control, COVID-19 Vaccines/adverse effects ; Humans ; SARS-CoV-2 |
| مستخلص: | COVID 19 is an infectious disease caused by severe acute respiratory syndrome corona virus 2. Thromboembolism has been a characteristic manifestation in most of the severely ill COVID-19 patients. Thromboembolism in COVID 19 infection is attributed to injury to the vascular endothelial cell, hypercoagulability and blood stasis. The hypercoagulable state of blood and thrombophilic diseases leads to hypercoagulability. COVID 19 infected patients with pre-existing hypercoagulable disorders have higher risk of developing thrombosis and thromboembolism and such thrombotic episodes may prove to be severely morbid in these patients. As immune-prophylaxis COVID 19 vaccines are being administered to the public. The known side effects of the COVID 19 vaccine are mild to moderate and include fever, chills, nausea, vomiting, headache, fatigue, myalgia, malaise, pain and swelling at injection site and diarrhea. Thrombosis with thrombocytopenia has been noted as a rare side effect of COVID 19 vaccine. Such side effect of COVID 19 vaccine in patients of hypercoagulable disorder may prove to be fatal. The health care workers should be cautious and judicious in managing such patients. A detailed lab profile for coagulable state of blood should be carried out in all patients COVID 19 infected patients with pre-existing hypercoagulability diseases. The patients should also be health educated regarding side effects of vaccine especially with those indicating thrombosis and they should be warranted to receive immediate medical care in case of any side effects or complications. Paucity of literature gave us an impetus to review management profile in patients of hypercoagulable disorders. (© 2021 Walter de Gruyter GmbH, Berlin/Boston.) |
| References: | Huang, C, Wang, Y, Li, X, Ren, L, Zhao, J, Hu, Y, et al.. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet . 2020;395:497–506. https://doi.org/10.1016/s0140-6736(20)30183-5 . (PMID: 10.1016/s0140-6736(20)30183-5) Ruan, Q, Yang, K, Wang, W, Jiang, L, Song, J. Correction to: clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intens Care Med . 2020;46:1294–7. https://doi.org/10.1007/s00134-020-06028-z . (PMID: 10.1007/s00134-020-06028-z) Klok, FA, Kruip, M, van der Meer, NJM, Arbous, MS, Gommers, D, Kant, KM, et al.. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res . 2020;191:145–7. https://doi.org/10.1016/j.thromres.2020.04.013 . (PMID: 10.1016/j.thromres.2020.04.013) Menter, T, Haslbauer, JD, Nienhold, R, Savic, S, Hopfer, H, Deigendesch, N, et al.. Postmortem examination of COVID-19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings in lungs and other organs suggesting vascular dysfunction. Histopathology . 2020;77:198–209. https://doi.org/10.1111/his.14134 . (PMID: 10.1111/his.14134) https://www.who.int/news-room/feature-stories/detail/side-effects-of-covid-19-vaccines . 31st March 2021. https://www.ema.europa.eu/en/news/astrazenecas-covid-19-vaccine-ema-finds-possible-link-very-rare-cases-unusual-blood-clots-low-blood . 7th April 2021. https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-vaxzevria-previously-covid-19-vaccine-astrazeneca_en.pdf Dissemination of Direct Health Care Professional . 24th March 2021. Nopp, S, Moik, F, Jilma, B, Pabinger, I, Ay, C. Risk of venous thromboembolism in patients with COVID-19: a systematic review and meta-analysis. Res Pract Thromb Haemost . 2020;4:1178–91. https://doi.org/10.1002/rth2.12439 . (PMID: 10.1002/rth2.12439) Nahum, J, Morichau-Beauchant, T, Daviaud, F, Echegut, P, Fichet, J, Maillet, JM, et al.. Venous thrombosis among critically ill patients with coronavirus disease 2019 (COVID-19). JAMA Netw Open . 2020;3:e2010478. https://doi.org/10.1001/jamanetworkopen.2020.10478 . (PMID: 10.1001/jamanetworkopen.2020.10478) Zhou, F, Yu, T, Du, R, Fan, G, Liu, Y, Liu, Z, et al.. Clinical course and risk factor for mortality of adult patients with COVID 19 in Wuhan; China: a retrospective cohort study. Lancet . 2020;399:1054–62. https://doi.org/10.1016/s0140-6736(20)30566-3 . (PMID: 10.1016/s0140-6736(20)30566-3) Tang, N, Li, D, Wang, X, Sun, Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost . 2020;18:844–7. https://doi.org/10.1111/jth.14768 . (PMID: 10.1111/jth.14768) Henry, BM, Vikse, J, Benoit, S, Favaloro, EJ, Lippi, G. Hyperinflammation and derangement of renin-angiotensin-aldosterone system in COVID-19: a novel hypothesis for clinically suspected hypercoagulopathy and microvascular immunothrombosis. Clin Chim Acta 2020;507:167–73. https://doi.org/10.1016/j.cca.2020.04.027 . (PMID: 10.1016/j.cca.2020.04.027) Kichloo, A, Dettloff, K, Aljadah, M, Albosta, M, Jamal, S, Singh, J, et al.. COVID-19 and hypercoagulability: a review. Clin Appl Thromb Hemost . 2020;26:1–9. https://doi.org/10.1177/1076029620962853 . (PMID: 10.1177/1076029620962853) Ackermann, M, Stijn, E, Kuehnel, M, Haverich, A. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N Engl J Med . 2020;383:120–8. https://doi.org/10.1056/nejmoa2015432 . (PMID: 10.1056/nejmoa2015432) Connors, JM, Levy, JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood . 2020;135:2033–40. https://doi.org/10.1182/blood.2020006000 . (PMID: 10.1182/blood.2020006000) McGonagle, D, O’Donnell, JS, Sharif, K, Emery, P, Bridgewood, C. Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia. Lancet Rheumatol . 2020;2:e437–45. https://doi.org/10.1016/s2665-9913(20)30121-1 . (PMID: 10.1016/s2665-9913(20)30121-1) Nopp, S, Moik, F, Jilma, B, Pabinger, I, Ay, C. Risk of venous thromboembolism in patients with COVID-19: a systematic review and meta-analysis. Res Pract Thromb Haemost . 2020;4:1178–91. https://doi.org/10.1002/rth2.12439 . (PMID: 10.1002/rth2.12439) Henry, BM, Benoit, SW, Hoehn, J, Lippi, G, Favaloro, EJ, Benoit, JL. Circulating plasminogen concentration at admission in patients with coronavirus disease 2019 (COVID-19). Semin Thromb Hemost . 2020;46:859–62. https://doi.org/10.1055/s-0040-1715454 . (PMID: 10.1055/s-0040-1715454) Thomas, RH. Hypercoagulability syndromes. Arch Intern Med . 2001;161:2433–9. https://doi.org/10.1001/archinte.161.20.2433 . (PMID: 10.1001/archinte.161.20.2433) Kumar, DR, Hanlin, E, Glurich, I, Mazza, JJ, Yale, SH. Virchow’s contribution to the understanding of thrombosis and cellular biology. Clin Med Res . 2010;8:168–72. https://doi.org/10.3121/cmr.2009.866 . (PMID: 10.3121/cmr.2009.866) Previtali, E, Bucciarelli, P, Passamonti, SM, Martinelli, I. Risk factors for venous and arterial thrombosis. Blood Transfus . 2011;9:120–38. https://doi.org/10.2450/2010.0066-10 . (PMID: 10.2450/2010.0066-10) Blaisdell, FW. Acquired and congenital clotting syndromes. World J Surg . 1990;14:664–9. https://doi.org/10.1007/bf01658823 . (PMID: 10.1007/bf01658823) Jiang, M, Mu, J, Shen, S, Zhang, H. COVID-19 with preexisting hypercoagulability digestive disease. Front Med . 2021;7:1073. https://doi.org/10.3389/fmed.2020.587350 . (PMID: 10.3389/fmed.2020.587350) Rajani, R, Björnsson, E, Bergquist, A, Danielsson, Å, Gustavsson, A, Grip, O, et al.. The epidemiology and clinical features of portal vein thrombosis: a multicentre study. Aliment Pharmacol Ther . 2010;32:1154–62. https://doi.org/10.1111/j.1365-2036.2010.04454.x . (PMID: 10.1111/j.1365-2036.2010.04454.x) Yuhara, H, Steinmaus, C, Corley, D, Koike, J, Igarashi, M, Suzuki, T, et al.. Meta-analysis: the risk of venous thromboembolism in patients with inflammatory bowel disease. Aliment Pharmacol Ther . 2013;37:953–62. https://doi.org/10.1111/apt.12294 . (PMID: 10.1111/apt.12294) Zezos, P, Kouklakis, G, Saibil, F. Inflammatory bowel disease and thromboembolism. World J Gastroenterol . 2014;20:13863–78. https://doi.org/10.3748/wjg.v20.i38.13863 . (PMID: 10.3748/wjg.v20.i38.13863) Nakashima, MO, Rogers, HJ. Hypercoagulable states: an algorithmic approach to laboratory testing and update on monitoring of direct oral anticoagulants. Blood Res . 2014;49:85–94. https://doi.org/10.5045/br.2014.49.2.85 . (PMID: 10.5045/br.2014.49.2.85) Tang, N, Bai, H, Chen, X, Gong, J, Li, D, Sun, Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost . 2020;18:1094–9. https://doi.org/10.1111/jth.14817 . (PMID: 10.1111/jth.14817) Miesbach, W, Makris, M. COVID-19: coagulopathy, risk of thrombosis, and the rationale for anticoagulation. Clin Appl Thromb Hemost . 2020;26:1–7. https://doi.org/10.1177/1076029620938149 . (PMID: 10.1177/1076029620938149) |
| فهرسة مساهمة: | Keywords: COVID 19 vaccine; hypercoagulability syndrome; hypercoagulable disorders; thrombocytopenia; thromboembolism; thrombosis |
| المشرفين على المادة: | 0 (COVID-19 Vaccines) |
| تواريخ الأحداث: | Date Created: 20211117 Date Completed: 20220315 Latest Revision: 20230308 |
| رمز التحديث: | 20231215 |
| DOI: | 10.1515/hmbci-2021-0037 |
| PMID: | 34786893 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1868-1891 |
|---|---|
| DOI: | 10.1515/hmbci-2021-0037 |